Aprovix AB

Our vision is to contribute to a cervical cancer free world by driving the transition to self-sampling for HPV-testing. Aprovix is a medical technology company that was founded in 2001, based on an idea by Professor Erik Wilander of Uppsala. Aprovix’s business concept is to supply healthcare providers with a tailored, cost-effective and reliable self sampling process combined with HPV testing for early detection of pre-stages of cervix cancer. Qvintip® is CE marked and is registered with the Swedish Medical Products Agency as a class 1 medical device. Qvintip® is also ISO certified. Additional, Qvintip® is now available for private customers. Qvintip® is an at-home, easy-to-use, self-test solution for Human Papillomavirus (HPV) enabling early detection of risk for cervical cancer with the same accuracy as sampling performed at a clinic. The device allows women to collect a vaginal fluid sample for lab analysis in the comfort of her own home. For more information please visit www.qvintip.com